SHH · 605507.SS
Guobang Pharma Ltd.
CN¥15.28+CN¥0.78 (+5.38%)
Guobang Pharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.65% below the high.
Loading market information…
SHH · 688289.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:29 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
Sansure Biotech Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Sansure Biotech Inc.’s forward annual dividend is CN¥0.53 per share, paid semi-annual. The forward yield is 3.46% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Sansure Biotech Inc.’s next earnings report is currently expected on Oct 30, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sansure Biotech Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sansure Biotech Inc., founded in Changsha, China, in 2008, is dedicated to the global development and commercialization of advanced diagnostic and research products. The company offers a diverse range of solutions, including upstream nucleic acid extraction kits, real-time PCR systems for both clinical and investigative purposes, and fluorescence detection platforms. Their extensive product portfolio encompasses diagnostic assays for critical conditions like the novel coronavirus, viral hepatitis, and AIDS. Furthermore, they provide blood screening and general extraction kits, tests for cancer-related biomarkers, and solutions for respiratory, sexually transmitted, digestive tract, prenatal, postnatal, and genetic diseases. Sansure Biotech also supplies essential laboratory instrumentation and various consumables, primarily serving hospitals and scientific laboratories worldwide.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Oct 23, 2024 |
| CN¥0.07 |
| CN¥315.62M |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥15.28+CN¥0.78 (+5.38%)
Guobang Pharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 28.65% below the high.
CN¥15.17+CN¥0.68 (+4.69%)
LBX Pharmacy Chain Joint Stock Company’s quoted price sits in the lower half of its reported 52-week range, 33.96% below the high.
CN¥14.15+CN¥0.35 (+2.54%)
Tofflon Science and Technology Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.54% below the high.
CN¥17.43-CN¥0.02 (-0.11%)
Xiamen Kingdomway Group Company’s quoted price sits in the upper half of its reported 52-week range, 18.87% below the high.
CN¥86.73+CN¥4.33 (+5.25%)
Shanghai MicroPort Endovascular MedTech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 30.23% below the high.
CN¥24.29+CN¥0.24 (+1.0%)
Mayinglong Pharmaceutical Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.52% below the high.
CN¥10.43+CN¥0.23 (+2.25%)
Autek China Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.95% below the high.
CN¥14.34+CN¥0.22 (+1.56%)
Hualan Biological Bacterin Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.57% below the high.
